Loading…

Relationship of PPARG overexpression with prognostic parameters in papillary thyroid carcinoma

chromosomal rearrangement is frequently seen in thyroid cancer, and overexpression has been shown in the follicular variant of papillary thyroid carcinoma, but not in papillary thyroid carcinoma other than the follicular variant. The main aim of this study was to investigate the frequency of overexp...

Full description

Saved in:
Bibliographic Details
Published in:Acta otorhino-laryngologica italica 2022-02, Vol.42 (1), p.34-40
Main Authors: Asya, Orhan, Yumuşakhuylu, Ali Cemal, Bağcı, Pelin, Kaya, Handan, Gönen, Ayşegül, Gündoğdu, Yavuz, Muradov, Tajaddın, Şahin, Akın, Oysu, Çağatay
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:chromosomal rearrangement is frequently seen in thyroid cancer, and overexpression has been shown in the follicular variant of papillary thyroid carcinoma, but not in papillary thyroid carcinoma other than the follicular variant. The main aim of this study was to investigate the frequency of overexpression among papillary thyroid carcinoma and if there were any variants of papillary thyroid carcinoma with overexpression other than the follicular variant. Immunohistochemical analysis of overexpression was performed using a monoclonal antibody in a series of 111 paraffin-embedded blocks of thyroid tumours. Of the patients in our study, 100 were diagnosed with papillary thyroid carcinoma, 9 with follicular adenoma and 2 with follicular carcinoma. staining was detected in 19 of the 111 cases. Sixteen patients with overexpression had papillary thyroid carcinoma and 3 had follicular adenoma. overexpression was detected mainly in follicular-variant papillary thyroid carcinoma. Vascular invasion, lymphatic invasion, thyroid capsule invasion and lymph node positivity were lower in patients with overexpression.
ISSN:1827-675X
0392-100X
1827-675X
DOI:10.14639/0392-100X-N1034